SOURCES SOUGHT
B -- Exosome RNA isolation using Norgen Protocol
- Notice Date
- 9/8/2014
- Notice Type
- Sources Sought
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- HHS-NIH-NHLBI-CSB-SBSS-(HG)-2014-263-DLM
- Archive Date
- 9/30/2014
- Point of Contact
- Dorothy Maxwell, Phone: 301-435-0352
- E-Mail Address
-
maxwelld@mail.nih.gov
(maxwelld@mail.nih.gov)
- Small Business Set-Aside
- Total Small Business
- Description
- This is a Small Business Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice." NORGEN URINE PRESERVATIVE (SPECIFIED BRAND NAME: NORGEN BIOTEK) A. BACKGROUND: The National Institutes of Health (NIH) mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. The Gibbons Laboratory administratively housed within NHGRI's Division of Intramural Research, conducts a wide portfolio of clinical research addressing the issue of minority health disparities, especially as they pertain to cardiovascular disease. The NHGRI/DIR Cardiovascular Disease Section (CDS), Gibbons Laboratory conducts a broad program of clinical and translational research seeking a greater understanding of the genomic basis of human cardiovascular disease. A major component of research centers on understanding transcriptome changes contributing to cardiovascular disease phenotypes such as resistant hypertension and coronary calcification. B. PURPOSE AND OBJECTIVES: miRNAs are an important class of biological molecules between 18-22 nucleotides in length which perform crucial functions in gene regulation through mechanisms such as knockdown of antisense transcripts. Recently, it has become possible to profile the comprehensive set of miRNAs in a sample through a method known as miRNA-Seq, based on Illumina chemistry for next-generation DNA sequencing. Exosomes are nanoparticles secreted into the extracellular spaces of human organ systems that are being recently recognized and containing crucial information in the form of their protein and RNA cargo. However, due to their small size and the extremely small quantities present, it requires personnel with high levels of training and expertise to be able to isolate exosomes and the RNA within them. The Gibbons lab currently possesses human urine samples from cases and controls for resistant hypertension, a cardiovascular disease phenotype. At the time of collection, these samples were treated with Norgen Urine Preservative, a reagent specifically designed to maintain DNA and RNA in pristine condition. The Gibbons lab is currently archiving in our cryorepository human urine samples from cases and controls for resistant hypertension, a cardiovascular disease phenotype. As part of this research, we intend to investigate transcriptional changes associated with such phenotypes in exosomes using miRNA-Seq. The current service being requested is to extract exosomal RNA from these samples that were earlier treated with Norgen preservative. C. LINE ITEMS: 1. Exosome RNA isolation from 1 mL urine samples using Norgen protocol, QC of RNA after isolation (5SrRNA Standard curve), Quantity: 180; and 2. NCode TM miRNA Amplification System sufficient for 180 samples, Amplification and QC for 180 samples, Quantity: 180. D. Anticipated Period of Performance: Base Year: September 2014 through September 2016 E. EVALUATION FACTOR: 1. Contractor shall use Norgen Urine Preservative; 2. Contractor shall use Norgen protocol; and 3. Contractor shall use Norgen preservation and isolation kits. F. Capability Statement /Information: Interested parties are expected to review this notice to familiarize itself with the requirements of this project. Failure to do so will be at your firm's own risk. The following information shall be included in the capability statement: 1. A general overview of the respondents' opinions about the difficulty and /or feasibility of the potential requirement, and any information regarding innovative ideas or concepts. 2. Information in sufficient details of the respondents' (a) staff expertise, including their availability, experience, and formal and other training; (b) current in-house capability and capacity to perform the work; (c) prior completed projects of similar nature; (d) corporate experience and management capability; and (e) examples of prior completed Government contracts, references, and other related information. 3. The respondents' DUNS number, organization name, address, point of contact, and size and type of business (e.g., 8(a), HUBZone, etc) pursuant to the North American Industry Classification System (NAICS) code: 541712, Research and Development in the Physical, Engineering, and Life Sciences (except biotechnology) small business size standard is 500. 4. Any other information that may be helpful in developing or finalizing the requirements of the potential acquisition. 5. The capability statement shall not exceed 20 single-sided pages (including all attachments, resumes, charts, etc.) presented in single-space and using a 12-point font size minimum, in either Microsoft Word or Adobe Portable Document Format (PDF), with 8-1/2 by 11 inch paper size, and 1 inch top, bottom, left and right margins. 6. All proprietary information should be marked as such. Statements should also include an indication of current certified small business status; this indication should be clearly marked on the first page of your capability statement (preferably placed under the eligible small business concern's name and address). Responses will be reviewed only by NIH personnel and will be held in a confidential manner. G. Closing Statement: All capability Statements sent in response to this SOURCES SOUGHT notice must be submitted electronically (via email) to Dorothy Maxwell, Contract Specialist, at maxwelld@mail.nih.gov in either MS Word or Adobe Portable Document Format (PDF), by September 15, 2014 7:30 A.M., EASTERN TIME under Solicitation Number: HHS-NIH-NHLBI-CSB-SBSS-(HG)-2014-263-DLM. FAXES ARE NOT ACCEPTED. All responses must be received by the specified due date and time in order to be considered. This Sources Sought Notice (SS) is for information and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the National Heart, Lung, and Blood Institute (NHLBI). The NHLBI does not intend to award a contract on the basis of responses nor otherwise pay for the preparation of any information submitted. As a result of this notice, the NHLBI may issue a Request for Quote (RFQ). THERE IS NO SOLICITATION AVAILABLE AT THIS TIME. However, should such a requirement materialize, no basis for claims against NHLBI shall arise as a result of a response to this notice or the NHLBI's use of such information as either part of our evaluation process or in developing specifications for any subsequent requirement. "Disclaimer and Important Notes. This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality. No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s)."
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/HHS-NIH-NHLBI-CSB-SBSS-(HG)-2014-263-DLM/listing.html)
- Record
- SN03500710-W 20140910/140909022510-9ed247df64e5ff3634826af04becd72d (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |